Study Investigator: Dr. Anthony Mutsaers
Graduate Student: Dr. Gabby Allegrini (DVSc)
Purpose of the Clinical Study
Palladia is a type of drug originally used to treat recurrent mast cell tumours in dogs. New evidence has shown that Palladia may be useful for treating other cancer types. Oral melanoma is a locally invasive and highly metastatic cancer. In some cases, even with aggressive therapy, survival times can be as little as 6 months. The use of Palladia, if other treatments have failed, or if traditional therapy is declined, may extend survival in these patients.
Is Your Pet Eligible?
Dogs with a confirmed diagnosis of oral melanoma through biopsy are eligible. Other specific criteria required to participate include measurable disease, and no previous history of chemotherapy administration. Dogs that have previously received the melanoma vaccine will still be eligible.
Visits / Samples Required
Multiple visits to OVC will be required for this study.
Financial Incentives
The cost of initial staging (blood work, chest x-rays and a biopsy), Palladia medication and associated dispensing and administration fees will be covered by the study.
